 |
|
Study produces conflicting findings on the use of anti-anemia drug in cancer patients
April 17, 2007LOS ANGELES - Results from a phase III drug trial indicate that an anti-anemia drug did not significantly decrease the need for blood transfusions in patients not on chemotherapy, and decreased overall patient survival when compared to placebo, according to researchers from the UCLA Medical Center at the 2007 Annual Meeting of the American Association for Cancer Research.
The drug, darbepoetin alfa (DA) is a synthetic form of erythropoietin, a hormone that signals the formation of new red blood cells from within the bone marrow. DA is commonly used as a means of combating anemia in cancer patients who are also receiving chemotherapy. Anemia in cancer patients can result from either chemotherapy or the cancer itself, and it has a measurable effect on quality of life and overall cancer survival.
While some cancer patients not undergoing chemotherapy are also given DA, previous placebo-controlled studies did not show that darbepoetin significantly reduced transfusion risk.
"While the study was not specifically designed to study survival rates, our results indicate a statistically significant decrease in patients given the drug versus those who were given placebo," said John Glaspy, M.D., professor at the University of California, Los Angeles School of Medicine. "Since erythropoietic agents are sometimes used in the U. S. to treat anemia and reduce transfusion risk in patients not on chemotherapy, these results are of concern to the research and clinical cancer communities."
The trial was designed to examine the ability of darbepoetin to reduce the need for blood transfusions in patients with active cancer not undergoing chemotherapy. The trial, held in clinical sites throughout North America, Europe and Australia was supported by the drug's manufacturer, Amgen.
Approximately 1,000 people were enrolled in the study, which was open to patients with most forms of cancer, except myeloid or acute leukemia and Burkitt's or lymphoblastic lymphoma. The most common cancers were non-small cell lung, breast and prostate cancer, with 82 percent of patients in disease stage III or IV. Patients were randomly assigned to receive either DA or a placebo, and given a weekly dose until week 16 or until the patient required a blood transfusion. The patients were then given an end-of-study examination at week 19, with two years of follow up to evaluate survival. During the study, researchers monitored each patient's hemoglobin level, an indicator of red blood cell production. Darbepoetin was withheld if the patient's hemoglobin count exceeded 13 grams per deciliter.
According to the researchers, fewer patients in the darbepoetin group required transfusions during the study, but the overall difference between the darbepoetin and placebo groups was not statistically significant. Subsequent analysis also showed a statistically significant increase in patient deaths - during the trial and in the follow up - amid the darbepoetin arm of the trial versus the placebo group, with 136 darbepoetin patient deaths versus 94 in the placebo group. Researchers say the trial was not designed to focus on survival, prognostic factors were not balanced at baseline and no specific study procedures were undertaken to determine the exact cause of death for these patients, beyond investigator attribution.
One confounding aspect of these study results was the different reactions among patients in the darbepoetin group, says Glaspy. When treated with darbepoetin, patients with kidney, prostate, or stomach cancers, non-Hodgkin's lymphoma, or multiple myeloma appeared to have worse survival outcomes. However, the opposite was seen among patients with breast, colon, ovarian, or cervical cancer. Indeed, many of these patients also achieved higher hemoglobin counts (yet still within the study's safety parameters). Survival rates were also better for patients in either group who did not need to receive transfusions.
"People with cancers like myeloma and lymphoma did substantially worse than people with diseases like breast cancer, for example," Glaspy said.
When the researchers notified Amgen of their preliminary results, the company issued a warning to doctors and informed the Food and Drug Administration as to the results of the trial. Subsequently, the manufacturer and FDA agreed to a "black box" warning for doctors about the drug's safety in this particular circumstance. "Certainly, the first concern is about safety, although nobody wants to see an increase in transfusions among patients already on the medication and doing well," said Glaspy.
"The findings will pose a particular puzzle to cancer researchers, as the exact mechanisms behind the observed decrease in patient survival is not clear," Glaspy said. "Likewise, we'll need to resolve these data in light of evidence that darbepoetin offers benefits for patients with certain types of cancer when used within chemotherapy. There are no obvious reasons for this discrepancy."
American Association for Cancer Research
"While the study was not specifically designed to study survival rates, our results indicate a statistically significant decrease in patients given the drug versus those who were given placebo," said John Glaspy, M.D., professor at the University of California, Los Angeles School of Medicine. "Since erythropoietic agents are sometimes used in the U. S. to treat anemia and reduce transfusion risk in patients not on chemotherapy, these results are of concern to the research and clinical cancer communities."
The trial was designed to examine the ability of darbepoetin to reduce the need for blood transfusions in patients with active cancer not undergoing chemotherapy. The trial, held in clinical sites throughout North America, Europe and Australia was supported by the drug's manufacturer, Amgen.
Approximately 1,000 people were enrolled in the study, which was open to patients with most forms of cancer, except myeloid or acute leukemia and Burkitt's or lymphoblastic lymphoma. The most common cancers were non-small cell lung, breast and prostate cancer, with 82 percent of patients in disease stage III or IV. Patients were randomly assigned to receive either DA or a placebo, and given a weekly dose until week 16 or until the patient required a blood transfusion. The patients were then given an end-of-study examination at week 19, with two years of follow up to evaluate survival. During the study, researchers monitored each patient's hemoglobin level, an indicator of red blood cell production. Darbepoetin was withheld if the patient's hemoglobin count exceeded 13 grams per deciliter.
According to the researchers, fewer patients in the darbepoetin group required transfusions during the study, but the overall difference between the darbepoetin and placebo groups was not statistically significant. Subsequent analysis also showed a statistically significant increase in patient deaths - during the trial and in the follow up - amid the darbepoetin arm of the trial versus the placebo group, with 136 darbepoetin patient deaths versus 94 in the placebo group. Researchers say the trial was not designed to focus on survival, prognostic factors were not balanced at baseline and no specific study procedures were undertaken to determine the exact cause of death for these patients, beyond investigator attribution.
One confounding aspect of these study results was the different reactions among patients in the darbepoetin group, says Glaspy. When treated with darbepoetin, patients with kidney, prostate, or stomach cancers, non-Hodgkin's lymphoma, or multiple myeloma appeared to have worse survival outcomes. However, the opposite was seen among patients with breast, colon, ovarian, or cervical cancer. Indeed, many of these patients also achieved higher hemoglobin counts (yet still within the study's safety parameters). Survival rates were also better for patients in either group who did not need to receive transfusions.
"People with cancers like myeloma and lymphoma did substantially worse than people with diseases like breast cancer, for example," Glaspy said.
When the researchers notified Amgen of their preliminary results, the company issued a warning to doctors and informed the Food and Drug Administration as to the results of the trial. Subsequently, the manufacturer and FDA agreed to a "black box" warning for doctors about the drug's safety in this particular circumstance. "Certainly, the first concern is about safety, although nobody wants to see an increase in transfusions among patients already on the medication and doing well," said Glaspy.
"The findings will pose a particular puzzle to cancer researchers, as the exact mechanisms behind the observed decrease in patient survival is not clear," Glaspy said. "Likewise, we'll need to resolve these data in light of evidence that darbepoetin offers benefits for patients with certain types of cancer when used within chemotherapy. There are no obvious reasons for this discrepancy."
American Association for Cancer Research
Blood Transfusion Current Events and Blood Transfusion News RSSBetter blood screening process needed to prevent babesiosis transmission
Babesiosis is a potentially dangerous parasitic disease transmitted by ticks and is common in the Northeast and the upper Midwest. Babesia lives inside of red blood cells, meaning it can also be transmitted through a blood transfusion from an infected but otherwise asymptomatic blood donor.
Study dispels myth that new residents cause increase in medical errors in July
New research published in the September issue of the Journal of the American College of Surgeons challenges the widely held belief that more medical errors occur in teaching hospitals during the month of July due to the influx of new graduates from medical and nursing schools - also known as the "July Phenomenon."
Blood transfusion study: Less is more
A new study suggests that blood transfusions for hospitalized cardiac patients should be a last resort because they double the risk of infection and increase by four times the risk of death.
Hepatitis C infection: treatment options equally effective, likelihood of success known early on
Results of a long-awaited study of 3,070 American adults at Johns Hopkins and 118 other U.S. medical centers show that treatment with either of the two standard antiviral drug therapies is safe and offers the best way for people infected with hepatitis C to prevent liver scarring, organ failure and death.
Pre-chewed food could transmit HIV
Researchers have uncovered the first cases in which HIV almost certainly was transmitted from mothers or other caregivers to children through pre-chewed food.
Bleeding disorders going undiagnosed; new guidelines to help
Nearly one percent of the population suffers from bleeding disorders, yet many women don't know they have one because doctors aren't looking for the condition, according to researchers at Duke University Medical Center.
Blood transfusions and outcomes
An exhaustive review and analysis of the medical literature by a panel of experts at the International Consensus Conference on Transfusion and Outcomes (ICCTO) held this month in Phoenix concluded that there is little evidence to support a beneficial effect from the greatest number of transfusions currently being given to patients.
Screening to help prevent stroke in kids increases, but limited access a problem
The number of children with a certain blood disorder undergoing an ultrasound to help prevent stroke is up significantly in the past 10 years since the publication of a major study showing its benefits.
Study identifies characteristics of hospitals with low rates of surgical site infections
New research published in the December issue of the Journal of the American College of Surgeons (JACS) suggests that surgical procedures that are shorter in duration and the use of fewer blood transfusions characterize hospitals that have a lower incidence of surgical site infections (SSI).
ACP recommends routine HIV screening for all patients
On World AIDS Day, the American College of Physicians (ACP) is giving doctors a call-to-action to routinely encourage HIV screening to all of their patients older than 13 years. This new practice guideline appears on the Annals of Internal Medicine Web site at www.annals.org.
More Blood Transfusion Current Events and Blood Transfusion News Articles
 |
Modern Blood Banking And Transfusion Practices by Denise M. Harmening (Author), Denise M. Harmening (Editor) Modern Blood Banking and Transfusion Practices continues to set the standard for teaching and learning modern blood banking. Thorough, yet concise, the fifth edition begins with a review of basic science, plus the history of blood preservation, and continues to provide students with a working knowledge of modern blood banking as it focuses on the how and why of transfusion practice, presenting a perfect "crossmatch" of theory and practice. |
 |
Blood Banking and Transfusion Medicine: Basic Principles and Practice by Christopher D. Hillyer MD (Author), Leslie E. Silberstein MD (Author), Paul M. Ness MD (Author), Kenneth C. Anderson MD (Author), John D. Roback MD PhD (Author) Ever since the discovery of blood types early in the last century, transfusion medicine has evolved at a breakneck pace. This second edition of Blood Banking and Transfusion Medicine is exactly what you need to keep up. It combines scientific foundations with today's most practical approaches to the specialty. From blood collection and storage to testing and transfusing blood components, and finally cellular engineering, you'll find coverage here that's second to none. New advances in molecular genetics and the scientific mechanisms underlying the field are also covered, with an emphasis on the clinical implications for treatment. Whether you're new to the field or an old pro, this book belongs in your reference library. Integrates scientific foundations with clinical relevance to... |
|
Blood Transfusion by Simti Servizi Srl | |
 |
Standards for Blood Banks and Transfusion Services, 26th edition by American Association of Blood Banks (AABB) (Author) The 26th edition of Standards for Blood Banks and Transfusion Services details the latest standards of practice in blood banking and transfusion medicine, and includes a number of changes. Significant changes: Inclusion of pathogen inactivation to meet the requirement for bacteria detection. New standard addresses need to provide educational materials to parents when parental consent is required. Revised requirement for Apheresis, Platelets allows determination of pH at time of issue rather than at end of allowable storage. Changes to requirements for continuous monitoring of products. New standard requires process for communicating anonymous concerns regarding safety and quality to executive management or AABB. |
 |
Transfusion by Cold Blood, Lydia Pense Cold Blood was originally signed in 1969 by Bill Graham to his own label and went on to record six albums before disbanding in the late 1970s. The band was revived in the late 1980s and the current lineup started to coalesce in the mid-‘90s under the direction of guitarist Steve Dunne, which culminated in a triumphant return to the Fillmore in 1998. In 2001, DIG Music released Vintage Blood: Live! 1973, a previously unreleased powerhouse collection of songs including their signature version of "You Got Me Hummin’," recorded in an intimate studio setting before a live audience.At the same time, former Cold Blood member Skip Mesquite, who had a number of songs he’d written and thought would be well- suited for Lydia, came in contact with DIG Music. Armed with these great new... |
|
Transfusion of Blood and Blood Products Starring: Mosby | |
 |
Saving Lives with Serum Albumin. Doctors today know the riddle of why an injured man, his wounds perfectly treated, may still not recover. He may be a victim of "shock", a dangerous trend toward failure of blood circulation. Unless this trend is promptly reversed, the effect is fatal. Now doctors have anew tool to fight shock - a tool newer than blood transfusions or plasma. This discovery, concentrated Serum Albumin, when used in shock cases, actually draws fluid from the body tissues into the circulation to make up the loss. This Human Serum Albumin is made from the blood you donate. Squibb Laboratories were among the first to produce Serum Albumin for our Armed Forces. ..... 1944 Squibb Ad, A5132. This Item is an original Magazine ad, taken from a vintage magazine of the year indicated. The ad is suitable for framing and displaying in your home or office. The scan of this item was taken through plastic film, however it is an accurate representation of the item. The nominal size is 10.5 inches by 14 inches. |
|
Circulatory III: Blood Transfusions Video: Advanced Nursing Care Skills Video Series [VHS] Starring: Gaylene Bouska Altman, Agnes Morrison, Delmar Thomson Learning | |
 |
Blood Banking & Transfusion Medicine - 2nd Ed, 2007, Hillyer, Md; Et Al - Blood Bank Textbooks by Lab Products Blood Banking & Transfusion Medicine - 2nd Ed, 2007, Hillyer, MD; et al - Blood Bank Textbooks : Integrates scientific foundations with clinical relevance for clear understanding. Highlights advances in use of blood products and discusses current clinical controversies. Tableof Contents Part I. History 1. A Brief History of Blood Transfusion.Part II. Blood Banking A. Immunohematology i. Basic Principles 2. Principlesof the Immune System Central to Transfusion Medicine. 3. Principles of the Complement System Central to Transfusion Medicine. 4. Principles of Red Blood Cell Allo- and Autoantibody Formation and Function. ii. RedBlood Cell, Platelet and Leukocyte Antigens and Antibodies 5. Membrane Blood Group Antigens and Antibodies. 6. ABO and Related Antigens and Antibodies. 7. Rh, Kell,... |
 |
Blood Transfusion: Blood Being Given to a Patient from a Drip-Feed Bottle at St. James's Hospital Giclee Poster Print, 16x12 by Art.com Art.com is the world's largest retailer of art prints, posters, photographs, and framed artwork. With our huge selection of over 400,000 prints, you'll easily find the perfect piece for your home, office, or classroom. Our art is printed on quality paper. When you order framed artwork, the piece is built by our team of in-house professionals. Visit our Amazon store today at www.amazon.com/artdotcom to find Special Offers and search for products based on 'Artist Name' and 'Subject Categories' such as Movie, Music, Vintage, TV, Children, Travel, Kitchen, Museum Art, Animals, Floral, Motivational, and Sports. Art.com is dedicated to providing you with high quality products and service by offering you 100% satisfaction guaranteed. We ship internationally to over 80 countries. Decorate your... |
| © 2009 BrightSurf.com |